NAT2 exhibits genetic polymorphisms that lead to variations in enzyme activity among individuals. These polymorphisms categorize people into "slow acetylators" and "fast acetylators." Slow acetylators have reduced enzyme activity and are at a higher risk for adverse drug reactions and certain cancers due to the prolonged presence of toxic substances in their bodies. Fast acetylators, on the other hand, may rapidly detoxify some substances but could also activate certain pro-carcinogens more quickly.
